JP2013525495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525495A5 JP2013525495A5 JP2013509223A JP2013509223A JP2013525495A5 JP 2013525495 A5 JP2013525495 A5 JP 2013525495A5 JP 2013509223 A JP2013509223 A JP 2013509223A JP 2013509223 A JP2013509223 A JP 2013509223A JP 2013525495 A5 JP2013525495 A5 JP 2013525495A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- integer
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 110
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052742 iron Inorganic materials 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000002184 metal Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 206010065973 Iron Overload Diseases 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052768 actinide Inorganic materials 0.000 claims description 5
- 150000001255 actinides Chemical class 0.000 claims description 5
- 208000005980 beta thalassemia Diseases 0.000 claims description 5
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 5
- 150000002602 lanthanoids Chemical class 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 2
- 201000007994 Aceruloplasminemia Diseases 0.000 claims description 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 2
- 108700037009 Congenital atransferrinemia Proteins 0.000 claims description 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 2
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000007867 atransferrinemia Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 201000008230 cutaneous porphyria Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000037919 acquired disease Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 241000894007 species Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 230000009920 chelation Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 6-oxo-1-cyclohexa-2,4-dienylidene Chemical group 0.000 description 2
- 241001515796 Cebinae Species 0.000 description 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022979 Iron excess Diseases 0.000 description 1
- 230000010637 Metal Chelating Activity Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100001133 acute intoxication condition Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- BOFQWVMAQOTZIW-UHFFFAOYSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N1C(C=2C(=CC=CC=2)O)=NC(C=2C(=CC=CC=2)O)=N1 BOFQWVMAQOTZIW-UHFFFAOYSA-N 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229940051473 deferasirox oral suspension Drugs 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940024583 exjade Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33113810P | 2010-05-04 | 2010-05-04 | |
| US61/331,138 | 2010-05-04 | ||
| PCT/US2011/035211 WO2011140232A2 (en) | 2010-05-04 | 2011-05-04 | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525495A JP2013525495A (ja) | 2013-06-20 |
| JP2013525495A5 true JP2013525495A5 (https=) | 2014-06-26 |
Family
ID=44902334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509223A Pending JP2013525495A (ja) | 2010-05-04 | 2011-05-04 | 金属キレート化剤としてのデスアザデスフェリチオシン類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20130053387A1 (https=) |
| EP (1) | EP2566854A4 (https=) |
| JP (1) | JP2013525495A (https=) |
| CN (1) | CN103038223A (https=) |
| AU (1) | AU2011248158A1 (https=) |
| BR (1) | BR112012028321A2 (https=) |
| CA (1) | CA2798082A1 (https=) |
| NZ (1) | NZ603774A (https=) |
| WO (1) | WO2011140232A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201910900T4 (tr) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiyokin polieter analogları. |
| WO2008115433A1 (en) | 2007-03-15 | 2008-09-25 | University Of Florida | Desferrithiocin polyether analogues |
| MY163516A (en) * | 2008-07-14 | 2017-09-15 | Ferrokin Biosciences Inc | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| EP2459544A4 (en) * | 2009-07-27 | 2012-12-05 | Ferrokin Biosciences Inc | DESDAADESFERROTHIOCIN POLYETHERAL ANALOGUE PROGRUGS USING METAL CHLORIDE |
| US8993606B2 (en) | 2011-12-09 | 2015-03-31 | Ferrokin Biosciences, Inc. | Oral formulations for treating metal overload |
| EP3620161A1 (en) | 2011-12-16 | 2020-03-11 | University of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
| EP2928469A4 (en) * | 2012-12-07 | 2016-11-02 | Ferrokin Biosciences Inc | POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS |
| EP2953899A4 (en) * | 2013-02-11 | 2016-10-12 | Yeda Res & Dev | LANTHANID CLUSTER AND METHOD OF USE THEREOF |
| JP2016513652A (ja) | 2013-03-15 | 2016-05-16 | フェロキン バイオサイエンシーズ， インコーポレイテッド | デスアザデスフェリチオシン類似体の多形形態 |
| AU2014352780A1 (en) * | 2013-11-22 | 2016-06-09 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| KR20170140306A (ko) * | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도 |
| KR20240137106A (ko) * | 2016-08-05 | 2024-09-19 | 아브페로 파마슈티칼스, 인크. | 금속-매개 상태를 치료하기 위한 투여 요법 |
| TWI791362B (zh) | 2021-12-27 | 2023-02-01 | 財團法人工業技術研究院 | 有機金屬錯合物、包含其之觸媒組合物、以及聚烯烴的製備方法 |
| CN118561711B (zh) * | 2024-07-31 | 2024-11-22 | 爱斯特（成都）生物制药股份有限公司 | 一种制备n-[8-(2-羟基苯甲酰基)氨基]辛酸及其盐的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3002989A1 (de) * | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| AT500490A1 (de) | 2001-10-16 | 2006-01-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte |
| US20040132789A1 (en) | 2002-08-22 | 2004-07-08 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
| JPWO2004031163A1 (ja) | 2002-10-01 | 2006-02-02 | 株式会社カネカ | 光学活性α−置換システインまたはその塩の製造方法並びにその合成中間体及びその製造方法 |
| WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| JP2007505044A (ja) * | 2003-09-09 | 2007-03-08 | ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド | ポリアミン−金属キレーター接合体 |
| JP2005289890A (ja) * | 2004-03-31 | 2005-10-20 | Mitsubishi Pharma Corp | ムスカリン性アセチルコリン受容体結合阻害剤 |
| TR201910900T4 (tr) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiyokin polieter analogları. |
| US20080093812A1 (en) | 2006-05-22 | 2008-04-24 | Ronald Reed | Rolling baggage wheels and method for manufacturing the same |
| US20080138440A1 (en) | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| EP2101764A4 (en) * | 2006-12-12 | 2010-02-17 | Univ Florida | ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON |
| WO2008115433A1 (en) * | 2007-03-15 | 2008-09-25 | University Of Florida | Desferrithiocin polyether analogues |
| MY163516A (en) * | 2008-07-14 | 2017-09-15 | Ferrokin Biosciences Inc | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| CN101928281A (zh) * | 2009-06-24 | 2010-12-29 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| EP2459544A4 (en) | 2009-07-27 | 2012-12-05 | Ferrokin Biosciences Inc | DESDAADESFERROTHIOCIN POLYETHERAL ANALOGUE PROGRUGS USING METAL CHLORIDE |
| WO2011028255A2 (en) | 2009-08-25 | 2011-03-10 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof |
-
2011
- 2011-05-04 EP EP11778269.8A patent/EP2566854A4/en not_active Withdrawn
- 2011-05-04 BR BR112012028321A patent/BR112012028321A2/pt not_active IP Right Cessation
- 2011-05-04 NZ NZ603774A patent/NZ603774A/en not_active IP Right Cessation
- 2011-05-04 CA CA2798082A patent/CA2798082A1/en not_active Abandoned
- 2011-05-04 US US13/695,376 patent/US20130053387A1/en not_active Abandoned
- 2011-05-04 AU AU2011248158A patent/AU2011248158A1/en not_active Abandoned
- 2011-05-04 US US13/100,705 patent/US9045440B2/en not_active Expired - Fee Related
- 2011-05-04 CN CN2011800290386A patent/CN103038223A/zh active Pending
- 2011-05-04 WO PCT/US2011/035211 patent/WO2011140232A2/en not_active Ceased
- 2011-05-04 JP JP2013509223A patent/JP2013525495A/ja active Pending
-
2015
- 2015-05-27 US US14/722,422 patent/US20150259306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525495A5 (https=) | ||
| US20250375426A1 (en) | Pharmaceutical combination comprising a selective s1p1 receptor agonist | |
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| US20160038474A1 (en) | Compositions and methods for the modulation of hemoglobin (s) | |
| Choudhry et al. | Current status of iron overload and chelation with deferasirox | |
| Italia et al. | Experimental animal model to study iron overload and iron chelation and review of other such models | |
| JP7554253B2 (ja) | 輸血依存性β－サラセミア（ＴＤＴ）の治療で使用するためのフェロポーチン阻害剤 | |
| JP7770272B2 (ja) | 金属誘発性疾患を治療するための投与レジメン | |
| IL296586A (en) | Cyclophilin inhibitors and their uses | |
| JP2015500294A (ja) | 金属過剰症を治療する経口製剤 | |
| AU2020213713B2 (en) | Inositol phosphate compounds for use in increasing tissular perfusion | |
| Abdelrazik | Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience | |
| JP6179904B2 (ja) | ソラフェニブの副作用低減剤 | |
| Franchini | Recent acquisitions in the management of iron overload | |
| Nagler et al. | Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia | |
| KR101436551B1 (ko) | 고중성지방혈증 또는 고중성지방혈증-연관 질환의 예방 또는 치료용 약학 조성물 | |
| JP2006500357A (ja) | 多発性硬化症を処置するためのトレオスルファンおよびその誘導体の使用 | |
| McIntyre et al. | Deferasirox | |
| Hoffbrand et al. | Long term deferiprone chelation therapy | |
| Khan et al. | Serial serum ferritin levels for monitoring response to iron chelation therapy in patients of beta thalassemia major “Prospective cohort study” | |
| HK40009939B (en) | Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload | |
| HK40009939A (en) | Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload | |
| HK1176001A (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| Razavi | DFT Study and Investigation of Desferrioxamine and Deferiprone in Removal of Rhodium and Iron from Biological System | |
| Cappellini | ICL670: clinical outcome |